Laurie J.  Olson net worth and biography

Laurie Olson Biography and Net Worth

Director of Karuna Therapeutics
Laurie Olson is a seasoned pharmaceutical executive with more than 30 years of experience in commercial and corporate strategy. As a former Corporate Officer and Executive Leadership Team member at Pfizer Inc, Ms. Olson advanced from Marketing and Commercial development roles to serving as Executive Vice President of Strategy and Commercial Operations, leading approximately 2,000 colleagues in more than 100 countries at the time of her retirement from Pfizer in 2018.

During her role as Director of Corporate Strategy, she supported the organization in its achievement of greater strategic focus and renewed growth.  Her pharmaceutical career has included a keen focus on the interface between R&D and commercial organizations, fueled by a philosophy that the needs of patients are best realized via deep customer insights, data-driven decisions, and the seamless integration of scientific and marketing disciplines.  She is a recognized champion of innovation balanced with pragmatism to deliver results, a culture-builder of engaged colleagues, and a strong advocate for workplace diversity, equity, and inclusion.

Ms. Olson received a B.A in Economics from SUNY Stony Brook and an M.B.A. in Marketing from Hofstra University.  She also serves on the Board of Trustees of the Mystic Seaport Museum, the nation’s leading maritime museum, in Mystic, CT.

What is Laurie J. Olson's net worth?

The estimated net worth of Laurie J. Olson is at least $5.03 million as of April 1st, 2024. Ms. Olson owns 15,238 shares of Karuna Therapeutics stock worth more than $5,025,950 as of April 25th. This net worth estimate does not reflect any other investments that Ms. Olson may own. Learn More about Laurie J. Olson's net worth.

How do I contact Laurie J. Olson?

The corporate mailing address for Ms. Olson and other Karuna Therapeutics executives is 33 ARCH STREET SUITE 3110, BOSTON MA, 02110. Karuna Therapeutics can also be reached via phone at (857) 449-2244 and via email at [email protected]. Learn More on Laurie J. Olson's contact information.

Has Laurie J. Olson been buying or selling shares of Karuna Therapeutics?

Laurie J. Olson has not been actively trading shares of Karuna Therapeutics within the last three months. Most recently, Laurie J. Olson sold 1,000 shares of the business's stock in a transaction on Monday, July 3rd. The shares were sold at an average price of $215.65, for a transaction totalling $215,650.00. Following the completion of the sale, the director now directly owns 990 shares of the company's stock, valued at $213,493.50. Learn More on Laurie J. Olson's trading history.

Who are Karuna Therapeutics' active insiders?

Karuna Therapeutics' insider roster includes Stephen Brannan (Insider), James Healy (Director), Troy Ignelzi (CFO), Jeffrey Jonas (Director), Andrew Miller (COO), Laurie Olson (Director), Atul Pande (Director), Steven Paul (CEO), and Heather Preston (Director). Learn More on Karuna Therapeutics' active insiders.

Are insiders buying or selling shares of Karuna Therapeutics?

In the last twelve months, insiders at the sold shares 12 times. They sold a total of 89,119 shares worth more than $20,412,131.47. The most recent insider tranaction occured on March, 8th when insider Stephen K Brannan sold 5,000 shares worth more than $1,591,700.00. Insiders at Karuna Therapeutics own 13.2% of the company. Learn More about insider trades at Karuna Therapeutics.

Information on this page was last updated on 3/8/2024.

Laurie J. Olson Insider Trading History at Karuna Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
7/3/2023Sell1,000$215.65$215,650.00990View SEC Filing Icon  
4/3/2023Sell1,000$181.02$181,020.00View SEC Filing Icon  
10/11/2022Sell1,000$205.63$205,630.00View SEC Filing Icon  
8/15/2022Sell1,000$267.59$267,590.00View SEC Filing Icon  
5/27/2022Sell1,000$110.00$110,000.00View SEC Filing Icon  
2/15/2022Sell1,000$110.00$110,000.00View SEC Filing Icon  
11/15/2021Sell1,000$138.24$138,240.00View SEC Filing Icon  
6/7/2021Sell4,000$112.93$451,720.004,000View SEC Filing Icon  
See Full Table

Laurie J. Olson Buying and Selling Activity at Karuna Therapeutics

This chart shows Laurie J Olson's buying and selling at Karuna Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Karuna Therapeutics Company Overview

Karuna Therapeutics logo
Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate includes KarXT, an oral modulator of muscarinic receptors for the treatment of acute psychosis in patients with schizophrenia; and for the treatment of central nervous system disorders, such as negative and cognitive symptoms of schizophrenia and psychosis, as well as for the treatment of various peripheral tissues and dementia-related psychosis, including Alzheimer's disease. The company also focuses on developing other muscarinic-targeted drug candidates; and intends to develop lead candidature TRPC4/5 and KAR-2618 for the treatment of depressive disorder. Karuna Therapeutics, Inc. has a license agreement with Eli Lilly and Company, and Zai Lab (Shanghai) Co., Ltd; patent license agreement with PureTech Health LLC; and drug discovery partnership with Charles River Laboratories, as well as drug discovery collaboration with PsychoGenics, Inc. The company was formerly known as Karuna Pharmaceuticals, Inc. and changed its name to Karuna Therapeutics, Inc. in March 2019. Karuna Therapeutics, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.
Read More

Today's Range

Now: $329.83
Low: $329.83
High: $329.83

50 Day Range

MA: $325.43
Low: $313.97
High: $329.83

2 Week Range

Now: $329.83
Low: $158.38
High: $329.99

Volume

5 shs

Average Volume

832,048 shs

Market Capitalization

$12.58 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.18